Neurogenesis, Inc.
NEUN
Other OTC0.00
USD
- -
- -
ISIN
US64124F3010
CUSIP
64124F301
Return %
Stock
S&P500
1Y
0.00
18.46
3Y
-90.00
64.72
5Y
-99.50
72.79
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Keith J. Sullivan
- Full Time Employees
- 307
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 1241 Butler Road League City TX United States of America 77573
- IPO Date
- Jun 5, 1998
- Website
- neurogenesis.com
- Similar Companies
- Business
- Neurogenesis, Inc. is a company that creates and distributes specialized nutritional supplements, primarily serving the United States market. The firm provides products such as NeuBecalm'd, designed to alleviate the physiological and psychological impacts of both chronic and acute stress. Its offerings also include NeuBecalm'd Chewables, which aim to lessen stress and sharpen mental clarity. For those recovering from prolonged alcohol consumption, NeuRecover offers dietary support to naturally restore depleted neurotransmitters. Additionally, Neurogenesis supplies NeuReplenish, aiding in the revitalization and reconstruction of brain chemistry affected by sustained stimulant use. NeuRelieve supports the normalization of brain chemistry disrupted by long-term anti-anxiety medication, recommended for use with professional tapering guidance. NeuSlim is offered to assist in curbing desires for simple carbohydrates, moderating overall appetite, and fostering balanced dietary habits. The company also features the NeuBecalm'd/NeuRelieve Combo, formulated to support brain chemistry recovery following extended use of prescription pain relievers or opiate drugs, also intended for use in conjunction with supervised tapering. Neurogenesis, Inc. maintains research alliances, notably with the University of Edinburgh, working on developing diverse platform strategies to facilitate gene therapies. Established in 1984, the company's corporate headquarters are located in League City, Texas.